A Study of Circulating Endothelial Cell as Marker for Avastin (Bevacizumab) in Combination With Docetaxel Plus Xeloda (Capecitabine) as First Line Treatment for Patients With Locally Recurrent and Metastatic Breast Cancer

NCT00845910 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

22

Enrollment

INDUSTRY

Sponsor class

Stopped To be confirmed

Conditions

Breast Cancer

Interventions

DRUG: bevacizumab [Avastin]
DRUG: capecitabine [Xeloda]
DRUG: docetaxel

Sponsor

Hoffmann-La Roche